(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.
Cyramza is designed to block the blood supply that feeds tumors. It’s intended for people who…
FDA: Cyramza approval now includes non-small-cell lung CA
Sunday, December 14, 2014
FDA: Cyramza approval now includes non-small-cell lung CA
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment